Effect of a Novel Sweetener on the pH of Dental Plaque.
NCT ID: NCT00739778
Last Updated: 2008-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
24 participants
INTERVENTIONAL
2008-08-31
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
QUADRUPLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
food - novel sweetener
concentration to be isosweet with 4.7% sucrose
food vehicle blank
water blank
food - sweetener, positive control
4.7% sucrose in water
food - sweetener, negative control
non-cariogenic sweetener at concentration isosweet with 4.7% sucrose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or non-pregnant, non-lactating females ages 18 to 75 inclusive.
* Caries experience in the past year.
* More than 5 decayed, missing, or filled teeth demonstrating a high caries experience.
* Acidogenic plaque as demonstrated by a drop in pH to 5.7 or lower when challenged with sucrose rinse at the screening visit.
* Willing to abstain from all oral hygiene procedures, brushing and flossing, for 48 hours prior to each test day and drink only water for the four (4) hours prior to each test.
* Willing to abstain from the use of mouthwashes during the study.
Exclusion Criteria
* Systemic conditions which could influence the pH of the oral cavity (i.e., diabetes, salivary gland disorders etc.).
* Use of medications that would influence the pH of the oral cavity. Specifically, concomitant use of neuroleptics, atropine, chemotherapeutic agents, diuretics, antibiotics, antihistamines, decongestants, and muscle relaxants. Also, anticipated need for intermittent use of any medications in these classes or history of use during the 72 hours immediately prior to the screening visit.
* Patients with aggressive periodontitis, acute necrotizing ulcerative gingivitis, or gross decay at discretion of Investigator.
* Females who by self report are pregnant, lactating, planning to be pregnant during the study period, or women of childbearing potential who are unwilling to commit to the use of a medically approved form of contraception during the study period.
* Exposure to any investigational agent within the 30 days prior to study visit 1
* Individuals requiring prophylactic antibiotics
* Allergy or intolerance to food ingredients and products including artificial sweeteners.
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cargill
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
The Forsyth Institute
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Max Goodson, DDS, PhD
Role: PRINCIPAL_INVESTIGATOR
The Forsyth Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Forsyth Institute
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CFIS-08-001
Identifier Type: -
Identifier Source: org_study_id